Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NANP | Q8TBE9 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SELL | P14151 | 1/20 | 0.35 |
| ▸ | SELP | P16109 | 1/20 | 0.35 |
| ▸ | MAG | P20916 | 3/20 | 0.34 |
| ▸ | CD22 | P20273 | 8/20 | 0.33 |
| ▸ | NEU2 | Q9Y3R4 | 1/20 | 0.33 |
| ▸ | SIGLEC7 | Q9Y286 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16190434 | 1.00 | NANP (0.50) | NANPL3MBTL1SELLSELPMAG | |
| SCHEMBL19649551 | 1.00 | NANP (0.50) | NANPL3MBTL1SELLSELPMAG | |
| SCHEMBL16190386 | 1.00 | NANP (0.50) | NANPL3MBTL1SELLSELPMAG | |
| SCHEMBL8502846 | 1.00 | NANP (0.50) | NANPL3MBTL1SELLSELPMAG | |
| SCHEMBL18333558 | 1.00 | NANP (0.50) | NANPL3MBTL1SELLSELPMAG | |
| SCHEMBL19649587 | 1.00 | NANP (0.50) | NANPL3MBTL1SELLSELPMAG | |
| SCHEMBL15849913 | 1.00 | NANP (0.50) | NANPL3MBTL1SELLSELPMAG | |
| SCHEMBL17546140 | 1.00 | NANP (0.50) | NANPL3MBTL1SELLSELPMAG | |
| SCHEMBL18333560 | 1.00 | NANP (0.50) | NANPL3MBTL1SELLSELPMAG | |
| SCHEMBL31695084 | 0.89 | NANP (0.52) | NANPL3MBTL1SELLSELPMAG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10751418-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20130183270-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130183270-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| WO-2010111271-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG, INC. (AN OHIO CORPORATION) (US) | 2010-09-30 | — | — | WO | disclosed |
| US-20100080773-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. | 2010-04-01 | — | — | US | disclosed |
| US-20100080773-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100080773-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, FABP1, LIPC | NANP 4604/4885L3MBTL1 3487/4885SELL 782/4885 |
| US-20130183270-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, FABP1, LIPC | NANP 4604/4885L3MBTL1 3487/4885SELL 782/4885 |
| US-10751418-B2 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | NANP 4544/4885L3MBTL1 3625/4885SELL 1126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.